IL-BAI
BAI announced the finalists for the 2020 BAI Global Innovation Awards , the industry’s prestigious awards program that celebrates new and innovative solutions in the financial services industry worldwide.
Now in its tenth year, the BAI Global Innovation Awards recognizes leading financial services organizations on a global scale. This year, the awards drew hundreds of nominations from industry leaders demonstrating how their organizations used innovation to tackle their challenges in creative, impactful ways. Each nomination is evaluated by the Innovation Circle , a panel of global financial services innovation leaders who weigh each submission on originality and impact on consumers, employees, communities and the industry to determine the top innovations of the year.
The 2020 BAI Global Innovation Awards finalists are:
Consumer Products of Services Innovation
- Bank Pekao S.A., Poland: PeoPay KIDS
- CaixaBank S.A., Spain: HolaBank – Onboarding + mortgageNow
- FNB Life, South Africa: Dynamic Life – Home
- Meridian Credit Union, Canada: Meridian’s Price Drop
- OneConnect Smart Technology Co., Ltd. (Shenzhen), China: Smart Fast Claim
Customer Experience Innovation
- Bank of Montreal, Canada: BMO AI Cashflow Prediction
- Commonwealth Bank of Australia: Bill Sense
- DBS Bank Ltd, Singapore: DBS Chatbot – Guided Conversation
- Finicity, United States: Empowering the Customer Through Open Banking & Credit Decisioning
- FNB Life, South Africa: We’ve Got You COVI(R)D
Human Capital Innovation
- Citizens Financial Group, United States: Jamie Virtual Career Assistant
- SberBank, Russia: Employee Digital Care Program
- Ziraat Bank, Turkey: Hidden Power of Communication
Internal Process Innovation
- CaixaBank S.A., Spain: The New Mobility Section at Now
- DenizBank, Turkey: Digital Scorecard
- ICICI Bank, India: OPTIMUS – Payment Invoicing and ID Card Issuance System
- OneConnect Smart Technology Co., Ltd. (ShenZhen), China: Smart Contract Cloud Platform
- SberBank, Russia: Contact Center Internal Improvement Process
Marketing Innovation
- Emirates NBD Bank, United Arab Emirates: Emirates NBD Anti-Phishing "It Wasn't Me" Campaign
- imaginTech S.A., Spain: New imagin, a New Way to Communicate
- Synchrony, United States: Millie: A Multi-Channel Personal Finance Platform for Women
RegTech Innovation
- Abu Dhabi Global Market Financial Center (ADGM), United Arab Emirates: ADGM and ClauseMatch collaborate to launch Regulation 2.0
- Fino Payments Bank, India: Enterprise Risk & Fraud Management solution
- KAL ATM Software, Germany: New approach to costly and disruptive ATM hardware upgrades
- Ping An Technology (Shenzhen) Co., Ltd., China: Pingan Beehive Federated Intelligence Platform
Small Business Products or Services Innovation
- Aliasware, Inc., United States: PayVus Small Business Credit Card
- Banco Bradesco, Brazil: Open Banking Initiative: Portal MEI, Solutions for the Individual Micro Entrepreneur
- İşbank, Turkey: TekCap
- RBC Ventures, Canada: Ownr
Societal and Community Impact Innovation
- Citi Ventures Studio, United States: City Builder
- Union Bank of the Philippines: UBX SeekCap
- Woodforest National Bank, United States: Woodforest CEI-Boulos Opportunity Fund
Congratulations to all the finalists of the 2020 BAI Global Innovation Awards. The winners will be announced in February. To learn more please visit BAI Global Innovation Awards .
About BAI
As a nonprofit, independent organization, BAI has delivered the financial services industry’s most actionable insights for more than 95 years, enabling leaders to make smart business decisions every day. We provide in-depth, proprietary research to more than 40 of the top US banks, support more than 2,100 financial services organizations with compliance and professional development training, provide trusted, relevant thought leadership through BAI Banking Strategies reports, podcasts and webinars, and offer specialized events and programs. For more information, visit www.bai.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210128005646/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom